VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors
Analyses from the trial of the sodium-glucose transporter 2 inhibitor ertugliflozin in patients with type 2 diabetes helped better define positive effects the drug had on renal function.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors | Sodium